STREAM is the first large-scale, multi-country clinical trial to investigate shortened regimens for multidrugresistant tuberculosis (MDR-TB), and the first phase III trial to test the efficacy and safety of Bedaquiline, a new drug with a novel mechanism of action, within a shortened treatment regimen.
The trial established a Community Engagement (CE) Plan. The CE program was implemented at thirteen research sites within the STREAM trial, in seven countries. This paper sets out a summary of the experiences of CABs in connection with the STREAM clinical trial. It underlines relevant aspects that may be useful when planning and/or engaging communities in research. In conclusion, the experiences gained during STREAM, lead to both growing confidence in CE as a valuable process and community participation in advocacy.
Recent Abstracts
Analysing India’s Unique Subnational WHO FCTC Article 5.3 Policies and Their Implementation Across 17…
Strengthening the Tobacco Cessation Ecosystem
Activity Report 2025 – Brazil
More Data Better Health – Brazilian People’s Perceptions of Risk Factors for Cancer
Relatório de Atividades 2025 – Brasil
Mais Dados Mais Saúde – Percepções da população brasileira sobre fatores de risco…
What Primary Care Records Reveal About Cancer Signs and Symptoms
O que os prontuários da atenção primária revelam sobre sinais e sintomas de…
CRVS Performance Measurement and Monitoring Resource Kit
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council